These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 20814317

  • 1. A pilot, 8-week, placebo lead-in trial of quetiapine extended release for depression in midlife women: impact on mood and menopause-related symptoms.
    Soares CN, Frey BN, Haber E, Steiner M.
    J Clin Psychopharmacol; 2010 Oct; 30(5):612-5. PubMed ID: 20814317
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A.
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [Abstract] [Full Text] [Related]

  • 3. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.
    Katila H, Mezhebovsky I, Mulroy A, Berggren L, Eriksson H, Earley W, Datto C.
    Am J Geriatr Psychiatry; 2013 Aug; 21(8):769-84. PubMed ID: 23567397
    [Abstract] [Full Text] [Related]

  • 4. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.
    Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H.
    Depress Anxiety; 2012 Jul; 29(7):574-86. PubMed ID: 22753280
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies.
    Stein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H.
    Hum Psychopharmacol; 2011 Dec; 26(8):614-28. PubMed ID: 22143997
    [Abstract] [Full Text] [Related]

  • 6. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M.
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
    Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR, BOLDER II Study Group.
    J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
    [Abstract] [Full Text] [Related]

  • 8. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.
    Soares CN, Arsenio H, Joffe H, Bankier B, Cassano P, Petrillo LF, Cohen LS.
    Menopause; 2006 Dec; 13(5):780-6. PubMed ID: 16894334
    [Abstract] [Full Text] [Related]

  • 9. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
    Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L.
    Obstet Gynecol; 2006 Dec; 108(6):1402-10. PubMed ID: 17138773
    [Abstract] [Full Text] [Related]

  • 10. Effects of quetiapine extended release on sleep and quality of life in midlife women with major depressive disorder.
    Frey BN, Haber E, Mendes GC, Steiner M, Soares CN.
    Arch Womens Ment Health; 2013 Feb; 16(1):83-5. PubMed ID: 23143411
    [Abstract] [Full Text] [Related]

  • 11. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ.
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [Abstract] [Full Text] [Related]

  • 12. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate.
    Sheehan DV, Locklear J, Svedsäter H, Datto C.
    Int Clin Psychopharmacol; 2012 Sep; 27(5):239-48. PubMed ID: 22859063
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.
    Montgomery SA, Altamura AC, Katila H, Datto C, Szamosi J, Eriksson H.
    Int Clin Psychopharmacol; 2014 Mar; 29(2):93-105. PubMed ID: 24162081
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.
    Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D.
    J Affect Disord; 2010 Feb; 121(1-2):106-15. PubMed ID: 19903574
    [Abstract] [Full Text] [Related]

  • 15. Extended release quetiapine fumarate in patients with major depressive disorder: suicidality data from acute and maintenance studies.
    Weisler R, Montgomery SA, Earley WR, Szamosi J, Eriksson H.
    J Clin Psychiatry; 2014 May; 75(5):520-7. PubMed ID: 24816198
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy.
    Bauer M, McIntyre RS, Szamosi J, Eriksson H.
    Int J Neuropsychopharmacol; 2013 Sep; 16(8):1755-65. PubMed ID: 23672772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.